Annexin A2 and CD105 Expression in Pancreatic Ductal Adenocarcinoma is Associated with Tumor Recurrence and Prognosis |
Huang, Ya-Kai
(Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College)
Liu, Hong (Department of General Surgery, First Hospital of Shanxi Medical University) Wang, Xin-Zheng (First Affiliated Hospital of Henan University of Science and Technology) Zhu, Shan (First Affiliated Hospital of Henan University of Science and Technology) |
1 | Alonso-Alconada L, Santacana M, Garcia-Sanz P, et al (2014). Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. Int J Cancer. [Epub ahead of print] |
2 | Anderson P, Carrillo-Galvez AB, Garcia-Perez A, et al (2013). CD105 (endoglin)-negative murine mesenchymal stromal cells define a new multipotent subpopulation with distinct differentiation and immunomodulatory capacities. PLoS One, 8, 76979. DOI |
3 | Bharadwaj A, Bydoun M, Holloway R, et al (2013). Annexin A2 heterotetramer: structure and function. Int J Mol Sci, 14, 6259-305. DOI |
4 | Cheung R (2013). Racial and social economic factors impact on the cause specific survival of pancreatic cancer: a SEER survey. Asian Pac J Cancer Prev, 14, 159-63. 과학기술학회마을 DOI ScienceOn |
5 | Fonsatti E, Del Vecchio L, Altomonte M, et al (2001). Endoglin: An accessory component of the TGF-betabinding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol, 188, 1-7. DOI |
6 | Fonsatti E, Nicolay HJ, Altomonte M, et al (2010). Targeting cancer vasculature via endoglin/CD105: a novel antibodybased diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res, 86, 12-9. DOI |
7 | Fujiwara K, Ohuchida K, Ohtsuka T, et al (2013). Migratory activity of CD105+ pancreatic cancer cells is strongly enhanced by pancreatic stellate cells. Pancreas, 42, 1283-90. DOI |
8 | Gurluler E, Guner OS, Tumay LV, et al (2014). Serum annexin A2 levels in patients with colon cancer in comparison to healthy controls and in relation to tumor pathology. Med Sci Monit, 20, 1801-7. DOI |
9 | Kumar S, Ghellal A, Li C, et al (1999). Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res, 59, 856-61. |
10 | Li Y, Zhai Z, Liu D, et al (2014). CD105 promotes hepatocarcinoma cell invasion and metastasis through VEGF. Tumour Biol. |
11 | Ling Q, Jacovina AT, Deora A, et al (2004). Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest, 113, 38-48. DOI |
12 | Liu Y, Myrvang HK, Dekker LV (2014). Annexin A2 complexes with S100 proteins: structure, function and pharmacological manipulation. Br J Pharmacol. [Epub ahead of print] |
13 | Shen J, Person MD, Zhu J, et al (2004). Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res, 64, 9018-26. DOI ScienceOn |
14 | Miyata Y, Mitsunari K, Asai A, et al (2014). Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy. Prostate. [Epub ahead of print] |
15 | Okuse K, Malik-Hall M, Baker MD, et al (2002). Annexin II light chain regulates sensory neuron-specific sodium channel expression. Nature, 417, 653-6. DOI |
16 | Ryan DP, Hong TS, Bardeesy N (2014). Pancreatic adenocarcinoma. N Engl J Med, 371, 1039-49. DOI |
17 | Tadbir AA, Pardis S, Ashkavandi ZJ, et al (2012). Expression of Ki67 and CD105 as proliferation and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev, 13, 5155-9. 과학기술학회마을 DOI ScienceOn |
18 | Yang SF, Hsu HL, Chao TK, et al (2014). Annexin A2 in renal cell carcinoma: Expression, function, and prognostic significance. Urol Oncol. [Epub ahead of print] |
19 | Zheng L, Jaffee EM (2012). Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy. Oncoimmunology, 1, 112-4. DOI |